XORTX Therapeutics has acquired 1 company, including 1 in the last 5 years.
XORTX Therapeutics’ largest acquisition to date was in 2025, when it acquired Renal Anti-Fibrotic Therapeutic Program for $2M. The Company’s most targeted sectors include life science (100%).
3710 – 33rd Street NW,
Calgary, Alberta
T2L 2M1
Canada,
(403) 455-7727
www.xortx.com
| Date | Target |
Value
$mlns |
Transaction Type | Acquirer | Seller |
SRC
Link |
|---|---|---|---|---|---|---|
| 2025-10-17 |
Renal Anti-Fibrotic Therapeutic Program · Life Science
Rosebery, Australia The Renal Anti-Fibrotic Therapeutic Program includes a novel new chemical entity, VB4-P5, along with its associated intellectual property, regulatory documentation, and manufacturing data. The program is currently at the pre-IND (Investigational New Drug) stage of development and targets both rare and prevalent forms of kidney disease — areas with substantial unmet medical need. |
2 | Divestiture |
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
